Bass Loses Bid To Nix 'Ridiculous' Arthritis Drug Patent
The Patent Trial and Appeal Board on Tuesday refused a request from hedge fund manager Kyle Bass to review the validity of a patent on Horizon Pharma PLC's arthritis medication Vimovo,...To view the full article, register now.
Already a subscriber? Click here to view full article